| Similar Articles |
|---|
 |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age...   |
Bio-IT World
September 2006
Kevin Davies |
Pfizer's Global Survey of Pharmacological Space The pharma blends knowledge, computational chemistry and research informatics to build a unified database. Gathering all the data in one place offered greater control for indexing and data retrieval and management, enabling Pfizer scientists to perform global mapping. |
Bio-IT World
March 10, 2003
Mark D. Uehling |
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together. |
Bio-IT World
May 19, 2004
John Russell |
Informatics Black Boxes ... Not! Vertex's chief technical officer, discusses informatics' bad reputation, buying vs. building, open-source tools, and ROI on IT. |
Bio-IT World
Dec 2006/Jan 2007
John Russell |
Setting the Systems Bio Syllabus An interview with David de Graaf about Pfizer's growing comfort with systems biology. |
Bio-IT World
August 13, 2002
Russell & Dodge |
Necessary Liaisons: Making Standards Work Caroline Kovac, IBM Corp.'s general manager for life sciences, talks about the need for standards and her take on the troubled informatics world. |
Bio-IT World
October 2005
Salvatore Salamone |
Masters of the Semantic Web The Semantic Web is just at its early stage of deployment. As with the original Web, the usefulness of a Semantic Web will grow as more data and sites support RDF and the other Semantic Web standards. |
Bio-IT World
March 17, 2004 |
Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006. |
Bio-IT World
Dec 2006/Jan 2007
Allison Proffitt |
'An Unfortunate Storm': Tripos CEO Discusses Company Future Tripos announced that it has successfully sold its Discovery Informatics business to Vector Capital. Despite the company's difficulties, including a collapsed share price, president and CEO John McAllister is upbeat about the company's future. |
Fast Company
June 2004
Bill Breen |
The Thrill of Defeat Want to know how to motivate people to take on tough odds? Ask the folks in Pfizer's labs, where managing failure is a fine art and superhuman persistence an everyday habit. |
Reactive Reports
Issue 57 |
Interview with Andrew Lemon With a background in Chemistry and a keen sense of business, this co-found of The Edge Software Consultancy helps global pharmaceutical companies increase the efficiency and productivity of their software tools. |
Bio-IT World
November 2006
Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. |
Bio-IT World
March 8, 2005
John Russell |
Debating Business Models for Bioinformatics Companies Nailing down a single formula for successfully selling bioinformatics products or services has proven elusive. Harvard Business School tackles informatics' basic question: Where's the money? |
Pharmaceutical Executive
July 1, 2005
Zaborowski, Hammer & Lawler |
Informatics Rules How global computer systems helped far-flung research centers at Roche work together |
Chemistry World
February 2, 2011
Andy Extance |
Pfizer to close historic UK site Most of the 2400 people employed at the Pfizer site in Sandwich, UK, will be made redundant over the next 18-24 months as the US pharma giant restructures its research operations. |
The Motley Fool
June 20, 2011
Luke Timmerman |
Pfizer's Idea to Fix the Drug Development Crisis, Which Probably Won't Work (But Just Might) In a worst-case scenario, Pfizer flushes a few hundred million dollars down the tubes. What's the best-case scenario? |
The Motley Fool
July 6, 2010
Luke Timmerman |
Rising From the Ashes of Pfizer: The Michigan Contract Research Organization Cluster Many of the people who honed their skills inside Pfizer and other big companies have found new entrepreneurial outlets to keep doing what they do best at a growing array of contract research organizations. |
Bio-IT World
June 12, 2002
Beth Schachter |
Informatics Moves to the Head of the Class The race is on to increase the quantity and quality of bio-IT training programs as government and academia bet the need will be great. Will the job market back up that bet? |
Bio-IT World
November 2006
Wendy Wolfson |
Oracle OpenWorld 2006: Pharma Stuck on Semantic Web At the recent Oracle OpenWorld conference, pharma executives offered evidence that some, at least, are using the semantic web to work smarter and lower drug development costs. |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
Bio-IT World
November 2005 |
Bridges and Boundaries in Drug Discovery Research Good communication, blurring cultural boundaries, and strong project governance may be as, if not more, important as sweeping technology solutions when it comes to converging discovery and IT and expediting drug development. |
The Motley Fool
January 14, 2008
Brian Lawler |
Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008. |
Bio-IT World
September 2006
John Russell |
Informatics Cornucopia Predictive Informatics, the hopeful title of a session at last month's Drug Discovery Technology & Development World Congress, remains an enticing but mostly elusive goal. Asked what systems biology would look in five years and what will constitute success, panelists offered the following. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Pharmaceutical Executive
March 1, 2009
Walter Armstrong |
Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary. |
Chemistry World
July 9, 2008
James Mitchell Crow |
Pharma goes green to cut costs The pharmaceutical industry's current drive to curb spending is helping to speed the adoption of green chemistry, say experts in the industry. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion. |
Bio-IT World
October 2005
Scott Lundstrom |
Semantic Web: Safety and Innovation Semantic Web technologies will create opportunities for improvements in discovery, development, and safety. Pharmas and biotechs should move aggressively to pilot the use of semantic technologies in these areas. |
Chemistry World
March 2011
Bea Perks |
Editorial: At the forefront The news that most of Pfizer's 2400 employees at Sandwich, U.K. will be made redundant over the next two years was met with surprise, disappointment and anger. |
Bio-IT World
May 2006
John Russell |
Buyers Panel: What Biopharma Wants What does big (and at least one little) biopharma really want from technology providers? That was the theme of an entertaining session at Bio-IT World's Expo, featuring top IT and informatics executives from Merck, Lilly, Pfizer, Novartis, and Infinity Pharmaceuticals. |
Bio-IT World
December 15, 2004
Salvatore Salamone |
Getting the Gobbledygook Out of Data Sharing W3C's Semantic Web initiative holds promise for life science's data-integration challenges. |
The Motley Fool
April 19, 2006
Brian Gorman |
Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge. |
Bio-IT World
February 2006
Robert M. Frederickson |
Experiments in Data Integration Teranode evolved from a group of University of Washington scientists and has rapidly become a leading developer of informatics software for bio-scientists. |
Bio-IT World
June 2006
Alan S. Louie |
Semantic Web at the Cusp of Reality Even with successful development of standards and access to the Semantic Web infrastructure, Semantic Web technology overall will not be successful without broad acceptance and adoption by the drug development industry. |
Bio-IT World
August 15, 2005
Salvatore Salamone |
Tripos Embraces Web Services To make it easier to incorporate its discovery informatics tools into high-throughput workflows, Tripos has partnered with pipeline vendor SciTegic and announced support for a Web services architecture. |
Bio-IT World
Dec 2005/Jan 2006
Salvatore Salamone |
W3C Forms Life Sciences Semantic Web Group The World Wide Web Consortium (W3C) announced the formation of a new group that seeks to bring life scientists and Semantic Web experts together to help improve the way data are accessed, shared, and analyzed. |
CIO
October 28, 2011
Kim S. Nash |
Pfizer's Future Depends on IT Transformation With its business model ailing, this pharmaceutical giant tries a new IT formula, including a loyalty discount card, mobile applications aimed at consumers, and a cloud-based tablet CRM system for physicians. |
Pharmaceutical Executive
August 1, 2011
William Looney |
Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation. |
The Motley Fool
January 7, 2010
Brian Orelli |
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. |
The Motley Fool
October 15, 2007
Brian Lawler |
Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note. |
BusinessWeek
February 28, 2005
Amy Barrett |
Pfizer's Funk Pfizer CEO Hank McKinnell helped pioneer the age of blockbuster drugs. The company now spends twice as much on sales and administrative expenses as it does on R&D. But a dearth of new products and fears over drug safety are hurting the entire industry. Is there a fix? |
The Motley Fool
June 15, 2010
Brian Orelli |
Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer. |
Chemistry World
May 14, 2014
Andy Extance |
Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca. |
The Motley Fool
September 11, 2007
Brian Lawler |
Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans. |
The Motley Fool
February 2, 2011
Brian Orelli |
Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks. |
The Motley Fool
March 26, 2009
Brian Orelli |
Big Pharma's R&D Model Is Broken Bigger isn't always better. |
Chemistry World
December 21, 2015
Katrina Kramer |
BioAtla and Pfizer to collaborate on antibody research BioAtla and Pfizer will share expertise to develop tumor-targeting antibodies chemically bound to cytotoxic drugs. |
BusinessWeek
October 31, 2008
Arlene Weintraub |
Pfizer CEO Kindler Has His Work Cut Out for Him Investors want a fresh perspective for post-Lipitor Pfizer, but they're not yet convinced outsider CEO Jeffrey Kindler is the one to bring it. |
